» Articles » PMID: 32382273

Real-World Experience with AGA Guidelines in the Management of Crohn's Disease Following Ileocolonic Resection: A Retrospective Cohort Study

Overview
Publisher Wiley
Specialty Gastroenterology
Date 2020 May 9
PMID 32382273
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Postoperative endoscopic recurrence (PER) is common in patients with Crohn's disease (CD) after surgery. The impact of the American Gastroenterological Association (AGA) guideline adherence on PER in real life remains unclear.

Methods: The postoperative management of CD patients undergoing ileocolonic resection with anastomosis from 2017 to 2018 was conducted based on the AGA guidelines. Colonoscopies were performed within one year after surgery. Clinical data and risk factors for endoscopic recurrence were analyzed focusing on postoperative pharmacological prophylaxis.

Results: All patients were at a high risk of postoperative recurrence according to the AGA guidelines. PER occurred in 29 (28.7%) of these patients. The overall PER rate was 39.2% at one year. The PER rate in patients treated with nitroimidazole, thiopurines, infliximab, or a combination of thiopurines and infliximab for postoperative prophylaxis was 88.1%, 34.1%, 20.5%, and 0%, respectively. Cox regression showed that smoking at the time of surgery and AGA guideline adherence were independent factors associated with PER (HR: 3.75, 95% CI: 1.36-10.33, = 0.01; HR: 0.36, 95% CI: 0.15-0.86, = 0.02). In addition, further investigation revealed that educational background was the main factor related to patients' nonadherence to AGA guidelines.

Conclusions: The majority of CD patients who undergo surgery in clinical practice may be at a high risk of disease recurrence. Thiopurines and infliximab are effective in preventing endoscopic recurrence. Guideline nonadherence is associated with PER at one year, thus indicating that there is room for improvement in adherence to the AGA guidelines.

Citing Articles

The Impact of Postoperative Prophylactic Medication on Long-Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease.

Ten Bokkel Huinink S, Bak M, Beelen E, Erler N, Silverberg M, Allez M Aliment Pharmacol Ther. 2025; 61(6):1019-1031.

PMID: 39856782 PMC: 11869158. DOI: 10.1111/apt.18496.


How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis.

van der Does de Willebois E, Bellato V, Duijvestein M, van Dieren S, Danese S, Sileri P Ann Surg Open. 2024; 5(1):e397.

PMID: 38883962 PMC: 11175939. DOI: 10.1097/AS9.0000000000000397.


Crohn's disease and clinical management today: How it does?.

da Silva Junior R, Apolonio J, de Souza Nascimento J, da Costa B, Malheiro L, Silva Luz M World J Methodol. 2024; 13(5):399-413.

PMID: 38229938 PMC: 10789097. DOI: 10.5662/wjm.v13.i5.399.


Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.

Gisbert J, Chaparro M Drugs. 2023; 83(13):1179-1205.

PMID: 37505446 PMC: 10462742. DOI: 10.1007/s40265-023-01916-2.


Post-operative prevention and monitoring of Crohn's disease recurrence.

Lee K, Cantrell S, Shen B, Faye A Gastroenterol Rep (Oxf). 2022; 10:goac070.

PMID: 36405006 PMC: 9667961. DOI: 10.1093/gastro/goac070.

References
1.
Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G . Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013; 7(12):e623-9. DOI: 10.1016/j.crohns.2013.04.020. View

2.
Regueiro M, Velayos F, Greer J, Bougatsos C, Chou R, Sultan S . American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. Gastroenterology. 2016; 152(1):277-295.e3. DOI: 10.1053/j.gastro.2016.10.039. View

3.
De Cruz P, Kamm M, Hamilton A, Ritchie K, Krejany E, Gorelik A . Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2014; 385(9976):1406-17. DOI: 10.1016/S0140-6736(14)61908-5. View

4.
Esser D, Cornillie F, Diamond R, Spiegel R . On the updated ECCO consensus guidelines for medical management of Crohn's disease. J Crohns Colitis. 2011; 5(2):165-6. DOI: 10.1016/j.crohns.2010.02.002. View

5.
Nguyen G, LaVeist T, Harris M, Datta L, Bayless T, Brant S . Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15(8):1233-9. PMC: 2799328. DOI: 10.1002/ibd.20883. View